{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-045670","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.960621+00:00","generated_at":"2026-05-30T03:20:08.477097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances","bullets":["Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.","Cash $235.7M as of Sept 30; expects runway into 2026.","R&D expenses $133.9M (down from $144.6M); G&A $76.6M (up from $51.8M) due to commercial prep.","Completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease; dosing ongoing.","Initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA approval for KRESLADI anticipated 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-045670","json":"https://secwatch.observer/filing/0001140361-24-045670.json","markdown":"https://secwatch.observer/filing/0001140361-24-045670.md","text":"https://secwatch.observer/filing/0001140361-24-045670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/0001140361-24-045670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/ef20038212_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:20:08.477097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}